Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

Garber, Alan, Dr ; Henry, Robert, MD ; Ratner, Robert, MD ; Garcia-Hernandez, Pedro A, MD ; Rodriguez-Pattzi, Hiromi, MD ; Olvera-Alvarez, Israel, MD ; Hale, Paula M, PhD ; Zdravkovic, Milan, MD ; Bode, Bruce, MD

The Lancet (British edition), 2009-02, Vol.373 (9662), p.473-481 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível